The synthesis and biological evaluation of nucleobases/tetrazole hybrid compounds: A new class of phosphodiesterase type 3 (PDE3) inhibitors.

[1]  A. Pałasz,et al.  In search of uracil derivatives as bioactive agents. Uracils and fused uracils: Synthesis, biological activity and applications. , 2015, European journal of medicinal chemistry.

[2]  M. Torres,et al.  Synthesis and Pharmacophore Modelling of 2,6,9-Trisubstituted Purine Derivatives and Their Potential Role as Apoptosis-Inducing Agents in Cancer Cell Lines , 2015, Molecules.

[3]  K. Abnous,et al.  Synthesis and biological evaluation of novel pyridine derivatives as potential anticancer agents and phosphodiesterase-3 inhibitors. , 2014, Bioorganic chemistry.

[4]  S. Behrouz,et al.  Silica Sulfuric Acid (SSA) as a Highly Efficient Heterogeneous Catalyst for Persilylation of Purine and Pyrimidine Nucleobases and Other N-Heterocycles Using Hmds , 2010 .

[5]  Norbert Weissmann,et al.  Targeting cancer with phosphodiesterase inhibitors , 2010, Expert opinion on investigational drugs.

[6]  Maryam Rameshrad,et al.  Synthesis and Immunomodulation of Human Lymphocyte Proliferation and Cytokine (Interferon‐γ) Production of Four Novel Malonitrilamides , 2009, Chemical biology & drug design.

[7]  W. Parker.  Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. , 2009, Chemical reviews.

[8]  L. Rassenti,et al.  Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia , 2008, Proceedings of the National Academy of Sciences.

[9]  S. Mousavi,et al.  Study of cytotoxic and apoptogenic properties of saffron extract in human cancer cell lines. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[10]  J. Kotera,et al.  Overview of PDEs and Their Regulation , 2007, Circulation research.

[11]  J. Grande,et al.  Cyclic Nucleotide Phosphodiesterase (PDE) Inhibitors: Novel Therapeutic Agents for Progressive Renal Disease , 2007, Experimental biology and medicine.

[12]  D. Grierson,et al.  The purines: potent and versatile small molecule inhibitors and modulators of key biological targets. , 2006, Bioorganic & medicinal chemistry.

[13]  S. Kwon,et al.  Cilostazol Prevents the Progression of the Symptomatic Intracranial Arterial Stenosis: The Multicenter Double-Blind Placebo-Controlled Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis , 2005, Stroke.

[14]  V. Manganiello,et al.  Characterization of phosphodiesterase 3 in human malignant melanoma cell line. , 2002, Anticancer research.

[15]  J. Mackey,et al.  Nucleoside analogues and nucleobases in cancer treatment. , 2002, The Lancet. Oncology.

[16]  E. Moon,et al.  Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  K. Sharpless,et al.  Preparation of 5-substituted 1H-tetrazoles from nitriles in water. , 2001, The Journal of organic chemistry.

[18]  V. Manganiello,et al.  Phosphodiesterase 3 as a potential target for therapy of malignant tumors in the submandibular gland , 2001, Anti-cancer drugs.

[19]  G. Piazza,et al.  Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  J. Beavo,et al.  Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Fujishige,et al.  Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)* , 1999, The Journal of Biological Chemistry.

[22]  K. Matsushima,et al.  Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase. , 1998, Biochemical and biophysical research communications.

[23]  J. Beavo,et al.  Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  James F. Smith,et al.  Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase* , 1998, The Journal of Biological Chemistry.

[25]  J. Cheng,et al.  Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. , 1998, Biochemical and biophysical research communications.

[26]  E. Degerman,et al.  Structure, Localization, and Regulation of cGMP-inhibited Phosphodiesterase (PDE3)* , 1997, The Journal of Biological Chemistry.

[27]  E. Degerman,et al.  Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. , 1995, Archives of biochemistry and biophysics.

[28]  E. Degerman,et al.  Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). , 1995, Cellular signalling.

[29]  V. Manganiello,et al.  Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. , 1993, The Journal of biological chemistry.

[30]  E. Degerman,et al.  Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  E. Degerman,et al.  Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. , 2001, Progress in nucleic acid research and molecular biology.

[32]  R. Johnstone,et al.  A rapid, simple, and mild procedure for alkylation of phenols, alcohols, amides and acids , 1979 .